Analysis: New cancer breakthroughs add pressure to control costs
By Deena Beasley (Reuters) - An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers a...
Read More »By Deena Beasley (Reuters) - An exciting class of new cancer drugs may boost patients' odds for survival, but healthcare providers a...
Read More »(Reuters) - Johnson & Johnson is voluntarily recalling about 32 million packages of its birth control pill Cilest in Europe, Asia an...
Read More »By Laura Zuckerman (Reuters) - Human ancestors in Africa about 3.4 million years ago expanded their diets beyond the leaves and frui...
Read More »
By Lisa Maria Garza DALLAS (Reuters) - Breast cancer charity Susan G. Komen for the Cure, which suffered a publicity backlash last y...
Read More »(Reuters) - Aveo Pharmaceuticals Inc said it would cut about 62 percent of its workforce, or 140 jobs, to focus on developing its mo...
Read More »By Soyoung Kim and Greg Roumeliotis NEW YORK (Reuters) - Private equity firms KKR & Co LP, Warburg Pincus LLC and Cinven Ltd are wei...
Read More »By Andrew M. Seaman NEW YORK (Reuters Health) - Despite the U.S. government offering hefty financial incentives to doctors for using...
Read More »By Genevra Pittman NEW YORK (Reuters Health) - Cholesterol-lowering drugs could be tied to more muscle problems than researchers pre...
Read More »By Genevra Pittman NEW YORK (Reuters Health) - The proportion of middle-aged American men being treated for low testosterone more th...
Read More »By Kathryn Doyle NEW YORK (Reuters Health) - Men taking drugs in the fluoroquinolone family were twice as likely to suffer serious k...
Read More »